Age-related Macular Degeneration Market to Exhibit Substantial Growth Rate | Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision

The Age-related Macular Degeneration (AMD) Market is anticipated to grow in the coming years, owing to the expected launch of emerging therapies and the increasing prevalence of AMD in the 7MM.
Companies across the globe are diligently working toward the development of novel treatment therapies, with a considerable amount of success over the years. Major pharma and biotech giants, such as Opthea Limited, Kodiak Sciences Inc, Outlook Therapeutics, Inc., and others, are developing drugs for the treatment of Wet-AMD, whereas companies like Apellis Pharmaceuticals, Alkeus Pharmaceuticals, Iveric Bio, and others are developing drugs for the treatment of Dry-AMD.

DelveInsight's " [https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Age-related Macular Degeneration market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Age-related Macular Degeneration market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Age-related Macular Degeneration Overview

Age-related macular degeneration (AMD) stands as a primary cause of severe, irreversible vision loss in developed nations globally, profoundly impacting the well-being of those affected. As life expectancy rises, contributing to a surge in reported cases, the condition places a significant strain on healthcare systems due to the costly nature of current treatment standards.

The progression of AMD results in central vision deterioration, rendering many patients unable to engage in activities like reading, writing, or discerning color and detail, thus compromising their overall quality of life. While the precise functional mechanisms of AMD remain partially understood, recent advancements in genetic technologies have facilitated the discovery of various genetic variations linked to the condition.

The anticipated introduction of potential therapies may expand the market size in the coming years, supported by a growing population diagnosed with age-related macular degeneration.

Age-related Macular Degeneration Market Key Facts

*
The Age-related Macular Degeneration (AMD) market in the seven major markets is segregated into two parts, Dry-AMD and Wet-AMD. As per our analysis and estimation, in 2021, the Age-related Macular Degeneration (AMD) market size was approximately USD 9,840 million, which is further expected to increase by 2032.

*
The United States accounts for the largest market size of Age-related Macular Degeneration compared to EU5 (Germany, Italy, France, Spain, and the United Kingdom) and Japan.

*
As per our estimation, in 2021, the market size of Dry AMD was approximately USD 1,377 million, and of Wet AMD was approximately USD 8,463 million.

*
The expected launch of potential therapy may increase market size in the coming years, assisted by an increase in the diagnosed prevalent population of Age-related Macular Degeneration.

*
Upcoming therapy such as OPT-302, KSI-301, RGX-314, AKST4290, and others has the potential to create a significant positive shift in the Wet-AMD market size.

*
The United States accounts for the largest market size of Age-related Macular Degeneration compared to EU5 (Germany, Italy, France, Spain, and the United Kingdom) and Japan.

*
In the year 2021, the total prevalent cases of AMD were approximately 51,743,000+ in the 7MM, which might increase at a CAGR of 1.6% by 2032.

*
The US accounted for approximately 17,282,000+ prevalent cases of AMD in the year 2021.

*
In EU-5 countries, the highest number of prevalent cases of AMD was observed in Germany, with 7,850,700+ cases in the year 2021, followed by France.

*
Among the 7MM, Japan accounted for approximately 21% of prevalent cases of AMD in the year 2021.

*
In the year 2021, the total diagnosed cases of AMD were approximately 38,807,500+ cases in the 7MM. The highest number of cases were diagnosed in the US.

*
In the 7MM, the analysis of type-specific cases of AMD revealed that there were approximately 3,880,000+ and 34,926,000+ cases of Wet-AMD and Dry-AMD, respectively, in the year 2021. These cases are expected to increase by multiple numbers of folds by 2032.

[https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Age-related Macular Degeneration market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Age-related Macular Degeneration market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Age-related Macular Degeneration Epidemiology Assessment

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.

The Report Covers the Age-related Macular Degeneration (AMD) Epidemiology, Segmented by -

*
Total Prevalent Cases of Age-related Macular Degeneration (AMD) in the 7MM (2019-2032)

*
Total Diagnosed Prevalent Cases of AMD in the 7MM (2019-2032)

*
Type-specific Diagnosed Prevalent Cases of AMD (Wet and Dry AMD) in the 7MM (2019-2032)

*
Total Age-specific Cases of Macular Degeneration (AMD) in the 7MM (2019-2032)

*
Total Diagnosed Dry AMD Cases by Stage in the 7MM (2019-2032) (Early, intermediate, and advanced)

*
Total Geographic Atrophy Cases by Visual Impairment in the 7MM (2019-2032)

Age-related Macular Degeneration Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Age-related Macular Degeneration market or expected to be launched during the study period. The analysis covers the Age-related Macular Degeneration market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Age-related Macular Degeneration pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Age-related Macular Degeneration Market Will Evolve and Grow by 2032 @ [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

The Leading Companies in the Age-related Macular Degeneration Therapeutics Market Include:

Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA In, Outlook Therapeutics, Inc., Unity Biotechnology, Inc, PanOptica, Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Novartis, Luxa Biotechnology, Gemini Therapeutics, and many more.

Age-related Macular Degeneration Drugs Covered in the Report Include:

*
OPT-302: Opthea Limited

*
KSI-301: Kodiak Sciences Inc.

*
RGX-314: Regenxbio

*
Danicopan (ALXN2040): Alexion Pharmaceuticals and AstraZeneca

*
EG-301: Evergreen Therapeutics

*
Pegcetacoplan: Apellis Pharmaceuticals

*
Zimura: Iveric bio

*
Luminate: Allegro Ophthalmics

*
NGM621: NGM Biopharmaceuticals

*
Elamipretide: Stealth BioTherapeutics

*
CPCB-RPE1: Regenerative Patch Technologies

*
OpRegen: CellCure Neurosciences/Lineage Cell Therapeutics/Roche

*
GT005: Gyroscope Therapeutic

And Many Others

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @ [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Contents

1. Key Insights

2. Executive Summary

3. Age-related Macular Degeneration Competitive Intelligence Analysis

4. Age-related Macular Degeneration Market Overview at a Glance

5. Age-related Macular Degeneration Disease Background and Overview

6. Age-related Macular Degeneration Patient Journey

7. Age-related Macular Degeneration Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Age-related Macular Degeneration Treatment Algorithm, Current Treatment, and Medical Practices

9. Age-related Macular Degeneration Unmet Needs

10. Key Endpoints of Age-related Macular Degeneration Treatment

11. Age-related Macular Degeneration Marketed Products

12. Age-related Macular Degeneration Emerging Drugs and Latest Therapeutic Advances

13. Age-related Macular Degeneration Seven Major Market Analysis

14. Attribute Analysis

15. Age-related Macular Degeneration Market Outlook (In US, EU5, and Japan)

16. Age-related Macular Degeneration Access and Reimbursement Overview

17. KOL Views on the Age-related Macular Degeneration Market

18. Age-related Macular Degeneration Market Drivers

19. Age-related Macular Degeneration Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Download the Sample PDF to Learn More About the Key Offerings of the Report @ [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=agerelated-macular-degeneration-market-to-exhibit-substantial-growth-rate-regeneron-pharmaceuticals-novartis-roche-opthea-limited-kodiak-sciences-inc-regenxbio-alkahest-inc-graybug-vision]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.